Conference abstract · 2017
Conference abstractPublished 27 Dec 2017
Crohn′s and ulcerative colitis
The John Hopkins Hospital, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Crohn's disease (CD) and ulcerative colitis (UC) are common and heterogeneous chronic inflammatory bowel disorders of childhood that account for up to 25% of all patients with inflammatory bowel disease (IBD). In CD, the familial pattern of disease concordance would suggest that genetics contribute to disease etiology. Children are more likely to have proximal small bowel disease complicated by stricture formation, fistulization and the need for surgical intervention. The predisposition for small bowel disease has been associated with mutations of the nucleotide oligomerization domain 2 (NOD2)/Caspase activation and recruitment domain 15 (CARD15) gene on chromosome 16 in 1/3 of patients with CD. Homozygous patients also show an early age at disease onset and a relatively high relative risk for isolated stricturing distal ileal disease. Although a vast number of other gene polymorphisms have been identified, the role for genetic testing in either the diagnosis or the therapeutic management of patients with CD has yet to be determined. Although, the precise age of onset of CD can be difficult to determine in children, subclinical phases of disease associate well with a decrease in weight and height velocity, and a delay in pubertal development. A confident distinction between CD and UC also remains a taxonomic dilemma in 25% of pediatric patients with IBD, despite recent technological advances in diagnostic techniques, including magnetic resonance enterography (MRE), serological testing, and more recently contrast enhanced ultrasound. The early introduction of biological therapies, either alone or concurrently with azathioprine or methotrexate have proven efficacy in maintaining long-term remission without corticosteroids. The monitoring of drug levels, as well as neutralizing antibodies against anti-TNF therapy has allowed physician's to individualize drug therapy to improve clinical response, and reduce the risk of drug induced toxicity. Novel biological and immunosuppressant treatment strategies are now in development in pediatric patients with IBD with the aim at improving overall treatment efficacy and avoid the need for surgery.
Subjects
Gastroenterology & HepatologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 16 Mar 2015
Dietary treatment for Crohn's disease, ulcerative colitis and irritable bowel syndrome
Conference abstract · 10 Jul 2013
Two novel diagnostic tests assess disease activity and predict therapeutic benefit of a novel antifibrotic drug in patients with collagenous colitis in contrast to Crohn?s and ulcerative colitis
Short communication · 23 Mar 2023
Ulcerative Colitis and Crohn Disease
Case report · 19 Jan 2021
Transformation of Ulcerative Colitis to Crohns Disease: A Case Report and Literature Review
More from this journal
The newest in Journal of Gastrointestinal & Digestive System.
Research article · 1 Jan 2026
Prospective Observational Study for the Evaluation of Efficacy and Safety Profile of Probiotics Food Supplement in Children with Acute Diarrhea
Case report · 11 Nov 2025
Bitter Guard: A Gut Wrenching Surprise
Research article · 18 Jun 2025
Ursodeoxycholic Acid Treatment of LPAC Presenting as Post Cholecystectomy Pain: Rationale and Design of a Randomised Trial
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Gastrointestinal & Digestive System
- SubjectGastroenterology & Hepatology
- BylineArticles whose byline prints “Carmen Cuffari”
